ERBB2 and breast cancer: In doing this, breast cancer cells overexpressing ErbB2 (SKBR3, AU565, and HCC1954) were treated with lovastatin, the FDA-approved tyrosine kinase inhibitors against ErbB2 (lapatinib and neratinib), or the combinations as indicated (Fig. 3a).